Related Experiment Video
Updated: Apr 26, 2026

Evaluation of Host-Pathogen Responses and Vaccine Efficacy in Mice
Published on: February 22, 2019
Shortcomings of pertussis vaccines: why we need a third generation vaccine
1Crucell Holland B.V. one of the Janssen Pharmaceutical Companies of Johnson & Johnson - Bacterial Vaccines Research and Development Archimedesweg 4-6, Leiden, 2333 CN, Netherlands.
Abstract:
First generation whole-cell (wP) and second generation acellular (aP) pertussis vaccines have been highly effective in preventing childhood deaths due to pertussis, yet both vaccines have drawbacks that have limited their long-term usefulness. These include issues of reactogenicity and potency in the case of wP, and limited durability of protection and the potential for selection of escape mutants in the case of aP. Neither vaccine prevents disease in neonatal infants who continue to die from pertussis. A third generation of pertussis vaccines that provides broad, durable protection is needed. In the meantime, countries using wP should continue to do so, while countries using aP need to consider policies and schedules that reduce pertussis transmission to unvaccinated infants. In this respect, maternal vaccination appears to be a promising solution.
More Related Videos
Related Concept Videos
Vaccinations
Pneumonia III: Complications and Assessment
Microorganisms in Medicine and Therapeutics
Diphtheria
Vaccines
Mechanism of Antibiotic Resistance in MRSA

